Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Work In Process (2017 - 2025)

Adma Biologics (ADMA) has disclosed Work In Process for 9 consecutive years, with $57.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process fell 6.23% year-over-year to $57.8 million, compared with a TTM value of $57.8 million through Dec 2025, down 6.23%, and an annual FY2025 reading of $57.8 million, down 6.23% over the prior year.
  • Work In Process was $57.8 million for Q4 2025 at Adma Biologics, up from $44.5 million in the prior quarter.
  • Across five years, Work In Process topped out at $62.1 million in Q1 2023 and bottomed at $43.2 million in Q2 2025.
  • Average Work In Process over 5 years is $53.1 million, with a median of $53.5 million recorded in 2024.
  • The sharpest move saw Work In Process skyrocketed 94.66% in 2021, then decreased 21.6% in 2025.
  • Year by year, Work In Process stood at $59.0 million in 2021, then fell by 4.74% to $56.2 million in 2022, then decreased by 11.66% to $49.6 million in 2023, then grew by 24.22% to $61.6 million in 2024, then dropped by 6.23% to $57.8 million in 2025.
  • Business Quant data shows Work In Process for ADMA at $57.8 million in Q4 2025, $44.5 million in Q3 2025, and $43.2 million in Q2 2025.